cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.15468/dl.ep44bw
title: Occurrence Download

description: A dataset containing 10730 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is Vaccinium uliginosum",
 "Year 1910-1955"
 ]
}

 The dataset includes 10730 records from 252 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0012265-251025141854904/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.j4q4em
title: Occurrence Download

description: A dataset containing 210 species occurrences available in GBIF matching the query:
{
 "and" : [
 "HasCoordinate is true",
 "HasGeospatialIssue is false",
 "OccurrenceStatus is Present",
 "TaxonKey is Argiope bruennichi",
 "Year 1910-1955"
 ]
}

 The dataset includes 210 records from 13 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0012267-251025141854904/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.5281/zenodo.16880066
title: Data for "Large megathrust earthquakes in cold mantle wedge corners under lawsonite blueschist facies"

description: Data repository for:

Large megathrust earthquakes in cold mantle wedge corners under lawsonite blueschist facies by Hao Zhang et al.



metagreywacke-rsfit3000.txt: results of RSFit3000

PG178.zip: raw friction data

XRD.raw: XRD report of PG178
DOI: 10.15468/dl.4a8z6f
title: Occurrence Download

description: A dataset containing 3468 species occurrences available in GBIF matching the query:
{
 "and" : [
 "Country is Thailand",
 "Year is 2012",
 "InstitutionCode is iNaturalist"
 ]
}

 The dataset includes 3468 records from 1 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0012268-251025141854904/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.60798/ex7c-mj97
title: Novel black soldier fly larvae-enriched aquafeed as a transformative strategy to impact growth, fillet quality and cost-effective production of African Catfish
DOI: 10.6084/m9.figshare.30404914.v1
title: Steady-State Visual-Evoked EEG Dataset for Visual Function Assessment via Biomarker Extractio

description: <pre>According to the data from the World Health Organization, patients with visual function disorders, such as amblyopia and intermittent exotropia, have increased significantly and become an important factor contributing to the global burden of disease.<br>Currently, existing research has found that many human visual function disorders can be reflected in abnormal brain activities without ocular damage. The main clinical methods currently rely on subjective psychophysical tests and ophthalmological examinations, and the detection and utilization of neural signals are insufficient. Moreover, when assessing patients with language expression disorders, including infants, or uncooperative subjects, these methods pose considerable challenges, thereby complicating the implementation of vision assessments and indicating certain limitations of traditional methods.<br>Therefore, this paper introduces a steady-state visual-evoked EEG (S2VEEG) dataset, which includes 60 amblyopia patients, 14 intermittent exotropia patients, and 30 individuals with normal visual function. These patients were carefully diagnosed and selected by professional ophthalmologists in the hospital. A 64-channel EEG cap was used to collect the EEG data records of the subjects under steady-state visual stimulation. These physiological data can be used to explore new possible physiological indicators of visual function and for visual function assessment using emerging artificial intelligence technologies, thus promoting the development of the visual function disorder detection field.<br>The paper extracts differential entropy and small-worldness property as features and uses SVM,RGCB and EmT classifiers for training. The results show that the recognition accuracy among amblyopia patients, intermittent exotropia patients, and individuals with normal visual function reaches 95.38$\%$. This classification performance indicates significant differences among patients with different degrees of visual function disorders, demonstrating the good usability of the S2VEEG dataset and verifying the potential of small-worldness property as a biomarker for visual function disorder detection.<br></pre>
DOI: 10.15468/dl.gpb3xy
title: Occurrence Download

description: A dataset containing 14377 species occurrences available in GBIF matching the query:
{
 "DatasetKey" : [
 "is ENGIE | Fauna Monitoring of the Serra do Assuruá Wind Farm Complex – Birds"
 ]
}

 The dataset includes 14377 records from 1 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0012271-251025141854904/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.uyajxg
title: Occurrence Download

description: A dataset containing 2667 species occurrences available in GBIF matching the query:
{
 "and" : [
 "Country is Thailand",
 "Year is 2013",
 "InstitutionCode is iNaturalist"
 ]
}

 The dataset includes 2667 records from 1 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0012272-251025141854904/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.5281/zenodo.17510271
title: COVID-19-Hospitalisierungen in Deutschland

description: Im Datensatz "COVID-19-Hospitalisierungen in Deutschland" des Robert Koch-Institutswerden täglich aktualisierte Informationen zu Hospitalisierungen im Zusammenhang mit COVID-19 basierend auf den Meldungen nach dem Infektionsschutzgesetz (IfSG) bereitgestellt. Neben tagesaktuellen Fallzahlen und Inzidenzen auf Bundes- und Länderebene enthält der Datensatz auch modellgestützte Schätzungen verzögert gemeldeter Hospitalisierungen mittels Nowcasting. Ziel ist es, die tatsächliche Belastung des Gesundheitssystems durch COVID-19 besser abzubilden, insbesondere durch die Berechnung adjustierter 7-Tage-Hospitalisierungsinzidenzen.
DOI: 10.6084/m9.figshare.30514298
title: Temporal bird species richness, migratory category and Environmental parameters of ten deserts of the globe.

description: In this study, leveraging crowdsourced bird occurrence records (GBIF) and multi-decadal hydro-meteorological datasets (ERA5, GLEAM), and vegetation data (AVHRR), we show how environmental filtering and functional shifts in avian assemblages drive divergent spatial and temporal species richness patterns across ten major deserts.
DOI: 10.6084/m9.figshare.30514298.v1
title: Temporal bird species richness, migratory category and Environmental parameters of ten deserts of the globe.

description: In this study, leveraging crowdsourced bird occurrence records (GBIF) and multi-decadal hydro-meteorological datasets (ERA5, GLEAM), and vegetation data (AVHRR), we show how environmental filtering and functional shifts in avian assemblages drive divergent spatial and temporal species richness patterns across ten major deserts.
DOI: 10.15468/dl.f6xu2s
title: Occurrence Download

description: A dataset containing 3818 species occurrences available in GBIF matching the query:
{
 "and" : [
 "Country is Thailand",
 "Year is 2014",
 "InstitutionCode is iNaturalist"
 ]
}

 The dataset includes 3818 records from 1 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0012273-251025141854904/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.6084/m9.figshare.26663018
title: Adverse events associated with teriparatide: a real-world disproportionality analysis of the FDA adverse event reporting system (FAERS)

description: Teriparatide is widely used for osteoporosis treatment in various patients, but its safety profile is not fully documented. This study analyzes the FDA pharmacovigilance database to assess teriparatide’s safety. Data from the first quarter (Q1) of 2004 to the third quarter (Q3) of 2023 were extracted and analyzed for disproportionality between teriparatide and adverse effects (AE). A total of 66,991 AE reports identified teriparatide as the principal suspect medication, aggregating to 222,116 individual AEs. Notably, healthcare professionals authored 16.1% of these reports (<i>n</i> = 10,809), whereas consumers accounted for the majority with 81.3% (<i>n</i> = 54,474). Teriparatide revealed a marked association with an increased propensity for musculoskeletal and connective tissue disorders (ROR,3.95; 95% CI, 3.91–3.99) at the System Organ Class (SOC) level. Concurrently, 199 preferred terms (PTs) displayed significant disproportionality across all four employed algorithms. Our study confirms several well-known adverse drug reactions and identifies potential safety issues associated with teriparatide treatment. This contributes to a deeper understanding of the complex relationship between adverse reactions and teriparatide. These findings emphasize the importance of continuous monitoring and ongoing surveillance to promptly identify and effectively manage adverse reactions, thereby enhancing overall patient safety and well-being.
DOI: 10.6084/m9.figshare.26663018.v2
title: Adverse events associated with teriparatide: a real-world disproportionality analysis of the FDA adverse event reporting system (FAERS)

description: Teriparatide is widely used for osteoporosis treatment in various patients, but its safety profile is not fully documented. This study analyzes the FDA pharmacovigilance database to assess teriparatide’s safety. Data from the first quarter (Q1) of 2004 to the third quarter (Q3) of 2023 were extracted and analyzed for disproportionality between teriparatide and adverse effects (AE). A total of 66,991 AE reports identified teriparatide as the principal suspect medication, aggregating to 222,116 individual AEs. Notably, healthcare professionals authored 16.1% of these reports (<i>n</i> = 10,809), whereas consumers accounted for the majority with 81.3% (<i>n</i> = 54,474). Teriparatide revealed a marked association with an increased propensity for musculoskeletal and connective tissue disorders (ROR,3.95; 95% CI, 3.91–3.99) at the System Organ Class (SOC) level. Concurrently, 199 preferred terms (PTs) displayed significant disproportionality across all four employed algorithms. Our study confirms several well-known adverse drug reactions and identifies potential safety issues associated with teriparatide treatment. This contributes to a deeper understanding of the complex relationship between adverse reactions and teriparatide. These findings emphasize the importance of continuous monitoring and ongoing surveillance to promptly identify and effectively manage adverse reactions, thereby enhancing overall patient safety and well-being.
DOI: 10.6084/m9.figshare.26819142
title: Drug-induced erectile dysfunction: a real-world pharmacovigilance study using the FDA adverse event reporting system database

description: The comprehensive quantitative and comparative risk data of drug-induced erectile dysfunction (ED) are still lacking, and this study aims to supplement this information. We reviewed all the ED reports in the FDA Adverse Event Reporting System (FAERS) database from 2004 to 2023 and summarized a potential ED culprit-drug list and its corresponding reporting frequency. The reporting odds ratio (ROR) method was used to conduct disproportionality analysis. A total of 20,098 ED reports were retrieved from the FAERS database, which recorded 734 different ED culprit-drugs, involving 74 drug classes. Finasteride was the drug with the highest reporting frequency, and urologicals was the drug class with the highest reporting frequency. In disproportionality analysis, 209 drugs with positive signals showed a close relationship with ED occurrence, among which finasteride was the drug with the highest signal strength. Among 209 drugs with positive signals, 27 were compound preparations, and the risk level of compound preparations was usually higher than their single active ingredient. Our study integrated quantitative and comparative ED risk data of 734 drugs by using the FAERS database, which can provide reference information for regulators, medical personnel, and others involved in drug management and use.
DOI: 10.6084/m9.figshare.26819142.v1
title: Drug-induced erectile dysfunction: a real-world pharmacovigilance study using the FDA adverse event reporting system database

description: The comprehensive quantitative and comparative risk data of drug-induced erectile dysfunction (ED) are still lacking, and this study aims to supplement this information. We reviewed all the ED reports in the FDA Adverse Event Reporting System (FAERS) database from 2004 to 2023 and summarized a potential ED culprit-drug list and its corresponding reporting frequency. The reporting odds ratio (ROR) method was used to conduct disproportionality analysis. A total of 20,098 ED reports were retrieved from the FAERS database, which recorded 734 different ED culprit-drugs, involving 74 drug classes. Finasteride was the drug with the highest reporting frequency, and urologicals was the drug class with the highest reporting frequency. In disproportionality analysis, 209 drugs with positive signals showed a close relationship with ED occurrence, among which finasteride was the drug with the highest signal strength. Among 209 drugs with positive signals, 27 were compound preparations, and the risk level of compound preparations was usually higher than their single active ingredient. Our study integrated quantitative and comparative ED risk data of 734 drugs by using the FAERS database, which can provide reference information for regulators, medical personnel, and others involved in drug management and use.
DOI: 10.6084/m9.figshare.26663018.v1
title: Adverse events associated with teriparatide:a real-world disproportionality analysis of the Fda adverse event reporting system (faers)

description: Teriparatide iswidely used for osteoporosis treatment in various patients, but its safetyprofile is not fully documented. This study analyzes the FDA pharmacovigilancedatabase to assess teriparatide’s safety. Data from thefirst quarter (Q1) of 2004 to the third quarter (Q3) of 2023 were extracted andanalyzed for disproportionality between teriparatide and adverse effects (AE). A total of66,991 AE reports identified teriparatide as the principal suspect medication,aggregating to 222,116 individual AEs. Notably, healthcare professionalsauthored 16.1% of these reports (<i>n</i> = 10,809), whereas consumers accounted for themajority with 81.3% (<i>n</i> = 54,474). Teriparatide revealed a marked association withan increased propensity for musculoskeletal and connective tissue disorders (ROR,3.95; 95% CI, 3.91–3.99) at the System Organ Class (SOC) level. Concurrently,199 preferred terms (PTs) displayed significant disproportionality across allfour employed algorithms. Our studyconfirms several well-known adverse drug reactions and identifies potentialsafety issues associated with teriparatide treatment. This contributes to adeeper understanding of the complex relationship between adverse reactions andteriparatide. These findings emphasize the importance of continuous monitoringand ongoing surveillance to promptly identify and effectively manage adversereactions, thereby enhancing overall patient safety and well-being.
DOI: 10.6084/m9.figshare.26781254
title: Safety profiles of tetracycline-class drugs: a pharmacovigilance analysis of the FAERS database

description: As synthesis technology advances, novel and efficient derivatives of tetracyclines are found. Three new antibiotics were approved within the past 18 years, and represent a new era in the use of tetracyclines. To gain further insight into adverse events linked to tetracyclines and better protect pediatric patients, ongoing monitoring of safety data is crucial. The FAERS data from the first quarter of 2004 to the third quarter of 2023 in the AERSMine were extracted to conduct disproportionality analysis. The association between five tetracyclines and adverse events was evaluated using reporting odds ratio, and their risk factors were explored by multivariate logistic regression analysis. Our study showed that thyroid gland disorders had the strongest signal in children. Patients aged 12–18 and treatment with minocycline are risk factors for thyroid adverse events (12–18: OR = 10.727 [7.113–16.177], <i>p</i> &lt; 0.0001; minocycline: OR = 17.025 [10.475–27.678], <i>p</i> &lt; 0.0001). Second-generation tetracycline and third-generation tetracycline ADR patterns differed. Blood fibrinogen decreased and hypofibrinogenaemia was primarily reported with tigecycline and eravacycline. This study provided basic evidence for further research on tetracyclines-related adverse events. However, the safety of third-generation tetracycline in children requires additional validation through a large-scale prospective study.
DOI: 10.6084/m9.figshare.26781254.v1
title: Safety profiles of Tetracycline-class drugs: a pharmacovigilance analysis of the FAERS database

description: As synthesis technology advances, novel and efficient derivatives of tetracyclines are found. Three new antibiotics, tigecycline, omadacycline, and eravacycline, approved within the past 18 years, and represent a new era in the use of tetracyclines. To gain further insight into adverse events linked to tetracyclines and better protect pediatric patients, ongoing monitoring of safety data is crucial. The FAERS data from the first quarter of 2004 to the third quarter of 2023 in the AERSMine were extracted to conduct disproportionality analysis. The association between five tetracyclines and adverse events was evaluated using reporting odds ratio, and their risk factors were explored by multivariate logistic regression analysis. Our study showed that endocrine disorders had the strongest signal in children, especially thyroid gland disorders. Patients aged 12–18 and treatment with minocycline are risk factors for thyroid adverse events(12–18: OR = 10.727 [7.113–16.177], <i>p</i> &lt; 0.0001; minocycline: OR = 17.025 [10.475-27.678], <i>p</i> &lt; 0.0001).Second-generation tetracycline and third-generation tetracycline ADR patterns differed. Blood fibrinogen decreased and hypofibrinogenaemia were primarily reported with tigecycline and eravacycline. The potential effect of minocycline on thyroid function in adolescents should be of concern. This study investigated adverse events highly associated with tetracyclines treatment, which provided basic evidence for further research on tetracyclines-related adverse events for children. However, the safety of third-generation tetracycline in children requires additional validation through a large-scale prospective study.
DOI: 10.6084/m9.figshare.26781254.v2
title: Safety profiles of tetracycline-class drugs: a pharmacovigilance analysis of the FAERS database

description: As synthesis technology advances, novel and efficient derivatives of tetracyclines are found. Three new antibiotics were approved within the past 18 years, and represent a new era in the use of tetracyclines. To gain further insight into adverse events linked to tetracyclines and better protect pediatric patients, ongoing monitoring of safety data is crucial. The FAERS data from the first quarter of 2004 to the third quarter of 2023 in the AERSMine were extracted to conduct disproportionality analysis. The association between five tetracyclines and adverse events was evaluated using reporting odds ratio, and their risk factors were explored by multivariate logistic regression analysis. Our study showed that thyroid gland disorders had the strongest signal in children. Patients aged 12–18 and treatment with minocycline are risk factors for thyroid adverse events (12–18: OR = 10.727 [7.113–16.177], <i>p</i> &lt; 0.0001; minocycline: OR = 17.025 [10.475–27.678], <i>p</i> &lt; 0.0001). Second-generation tetracycline and third-generation tetracycline ADR patterns differed. Blood fibrinogen decreased and hypofibrinogenaemia was primarily reported with tigecycline and eravacycline. This study provided basic evidence for further research on tetracyclines-related adverse events. However, the safety of third-generation tetracycline in children requires additional validation through a large-scale prospective study.
DOI: 10.6084/m9.figshare.27152507
title: Assessment of safety profile of ivabradine in real-world scenario using FDA adverse event reporting system database

description: Ivabradine is primarily indicated for patients with sinus rhythm and a heart rate ≥ 75 beats/min, who have NYHA class II-IV chronic heart failure with systolic dysfunction. There is currently a lack of large-scale, real-world studies concerning its drug adverse reactions. This research assesses the side effects of ivabradine by analyzing reports of adverse events (AEs) from the FDA’s Adverse Event Reporting System (FAERS) database. To evaluate the importance of these AEs, four sequential analytic strategies were utilized. In total, 2,701 ivabradine-related AE reports were identified in the FAERS database. We identified 26 ivabradine-induced AEs, each with more than 20 reports, including some significant AEs not mentioned on the product label. The timing of AEs was also analyzed, with the majority of AEs occurring within the first month of ivabradine use. Gender-specific analysis indicates that female have a higher risk of AEs, such as off-label use, tachycardia, drug effectiveness for unapproved indications, and rash compared to male. This study provides important information for maximizing the usage of ivabradine, increasing its efficacy, and reducing any possible negative effects. The actual clinical use of the medication will be greatly aided by this knowledge.
DOI: 10.6084/m9.figshare.27152507.v1
title: Assessment of safety profile of ivabradine in real-world scenario using FDA adverse event reporting system database

description: Ivabradine is primarily indicated for patients with sinus rhythm and a heart rate ≥ 75 beats/min, who have NYHA class II-IV chronic heart failure with systolic dysfunction. There is currently a lack of large-scale, real-world studies concerning its drug adverse reactions. This research assesses the side effects of ivabradine by analyzing reports of adverse events (AEs) from the FDA’s Adverse Event Reporting System (FAERS) database. To evaluate the importance of these AEs, four sequential analytic strategies were utilized. In total, 2,701 ivabradine-related AE reports were identified in the FAERS database. We identified 26 ivabradine-induced AEs, each with more than 20 reports, including some significant AEs not mentioned on the product label. The timing of AEs was also analyzed, with the majority of AEs occurring within the first month of ivabradine use. Gender-specific analysis indicates that female have a higher risk of AEs, such as off-label use, tachycardia, drug effectiveness for unapproved indications, and rash compared to male. This study provides important information for maximizing the usage of ivabradine, increasing its efficacy, and reducing any possible negative effects. The actual clinical use of the medication will be greatly aided by this knowledge.
DOI: 10.15468/dl.vwycjy
title: Occurrence Download

description: A dataset containing 5077 species occurrences available in GBIF matching the query:
{
 "and" : [
 "Country is Thailand",
 "Year is 2015",
 "InstitutionCode is iNaturalist"
 ]
}

 The dataset includes 5077 records from 1 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0012275-251025141854904/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.34740/kaggle/dsv/13594160
title: Peer-to-Peer Boliviano (BOB) Exchange Data